Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

811 - Triple Negative Breast Cancer: Survival and age at time of diagnosis among the Lebanese population (115P)


18 Nov 2017


Poster lunch


Cancer Prevention;  Breast Cancer


Cynthia Kassab


Annals of Oncology (2017) 28 (suppl_10): x26-x34. 10.1093/annonc/mdx654


C. Kassab1, F. Nasr2

Author affiliations

  • 1 Faculty Of Medicine, University Saint-Esprit of Kaslik, 446 - Juniyah/LB
  • 2 Faculty Of Medicine, University Saint-Esprit of Kaslik, Juniyah/LB


Abstract 811


Invasive triple-negative breast cancer accounts for 10-20% of breast cancers and is responsible for a high percentage of breast cancer-related deaths. It is indeed a very aggressive tumor that is associated with a poor prognosis with high risk of relapse and a short disease-free survival. It is treated by chemotherapy only and does not benefit from targeted therapy until now. The purpose of this study was to analyze progression-free survival (PFS) and overall survival (OS) after the change of therapeutic modalities, and the age at diagnosis of triple-negative breast cancer in Lebanese women and to compare the age distribution with a preceding Lebanese study and a recent American study of 38,813 patients nationwide.


Data were collected from hospitals and pathology laboratories across Lebanon. The collection was based on the following inclusion criteria: female diagnosed with an invasive TNBC between 2010 and 2016. PFS was studied in 193 cases, the overall survival analysis was done on 63 cases and the age at time of diagnosis on 387 cases. The statistical analysis was done using Student t tests.


PFS improved from 19 to 35 months after the change of therapeutic protocols and the OS increased from 19 to 23 months (p 


The new therapeutic protocols proved to be more effective, but screening programs must be done at an earlier age. The findings may be pertinent for the Lebanese patients and warrant further evaluation in different ethnic groups and populations.

Clinical trial identification


Legal entity responsible for the study

Holy Spirit University of Kaslik




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.